|
1
|
Norgern L, Hiatt WR, Dormandy JA, Nehler
MR, Harris KA and Fowkes FG; TASC II Working Group. Inter-society
consensus for management of peripheral arterial diseases (TASCII).
J Vasc Surg. 45(Suppl S): S5–S67. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Brodie BC: Lectures illustrative of
various subjects in pathology and surgery. London: A Spottiswoode;
1846
|
|
3
|
Charcot JMC: Sur la claudication
intermittente observe dans un cas d’obliteration complete de l’ une
des arteres iliaques primitives. CR Soc Biol (Paris).
5:2251858.
|
|
4
|
Stammers FA: Peripheral arterial disease;
some points of common interest to general and orthopaedic surgery.
J Bone Joint Surg Br. 36-B:209–217. 1954.PubMed/NCBI
|
|
5
|
Allen EV, Barker NW and Hines EA:
Peripheral Vascular Diseases. 1st edition. W.B. Saunders, Co;
Philadelphia, PA: pp. 343–401. 1946
|
|
6
|
O’Riordain DS and O’Donnell JA: Realistic
expectations for the patient with intermittent claudication. Br J
Surg. 78:861–863. 1991.PubMed/NCBI
|
|
7
|
Criqui MH, Langer RD, Fronek A, Feigelson
HS, Klauber MR, McCann TJ and Browner D: Mortality over a period of
10 years in patients with peripheral arterial disease. N Engl J
Med. 326:381–386. 1992.PubMed/NCBI
|
|
8
|
Leng GC, Lee AJ, Fowkes FG, Whiteman M,
Dunbar J, Housley E and Ruckley CV: Incidence, natural history and
cardiovascular events in symptomatic and asymptomatic peripheral
arterial disease in the general population. Int J Epidemiol.
25:1172–1181. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Brevetti G, Martone VD, Perna S,
Cacciatore F, Corrado S, Di Donato A and Di Iorio A: Intermittent
claudication and risk of cardiovascular events. Angiology.
49:843–848. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Brevetti G, Schiano V, Verdoliva S,
Silvestro A, Sirico G, De Maio J, Lanero S and Chiariello M:
Peripheral arterial disease and cardiovascular risk in Italy.
Results of the Peripheral Arteriopathy and Cardiovascular Events
(PACE) study. J Cardiovasc Med (Hagerstown). 7:608–613. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ridker PM: Are associations between
infection and coronary disease causal or due to confounding? Am J
Med. 106:376–377. 1999.PubMed/NCBI
|
|
12
|
Mendez MV, Scott T, LaMorte W, Vokonas P,
Menzoian JO and Garcia R: An association between periodontal
disease and peripheral vascular disease. Am J Surg. 176:153–157.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hung HC, Willett W, Merchant A, Rosner BA,
Ascherio A and Joshipura KJ: Oral health and peripheral arterial
disease. Circulation. 107:1152–1157. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wiesli P and Schulthess G: Effect of
roxithromycin treatment on the endothelial function of Chlamydia
pneumoniae seropositive men suffering from peripheral arterial
occlusive disease. Circulation. 106:e2262002.PubMed/NCBI
|
|
15
|
Wiesli P, Czerwenka W, Meniconi A, Maly
FE, Hoffmann U, Vetter W and Schulthess G: Roxithromycin treatment
prevents progression of peripheral arterial occlusive disease in
Chlamydia pneumoniae seropositive men: a randomized,
double-blind, placebo-controlled trial. Circulation. 105:2646–2652.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Krayenbuehl PA, Wiesli P, Maly FE, Vetter
W and Schulthess G: Progression of peripheral arterial occlusive
disease is associated with Chlamydia pneumoniae
seropositivity and can be inhibited by antibiotic treatment.
Atherosclerosis. 179:103–110. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Vance DE and Van den Bosch H: Cholesterol
in the year 2000. Biochim Biophys Acta. 1529:1–8. 2000.PubMed/NCBI
|
|
18
|
Hodgson JA: Treatise on the Diseases of
Arteries and Veins. Thomas Underwood; London, UK: 1815
|
|
19
|
Virchow R: Cellular Pathology. John
Churchill; London, UK: 1858
|
|
20
|
Osler W: Diseases of the arteries. Modern
Medicine: Its Practice and Theory. Lea and Febiger; Philadelphia,
PA: pp. 429–447. 1908
|
|
21
|
Ross: Atherosclerosis - an inflammatory
disease. N Engl J Med. 340:115–126. 1999. View Article : Google Scholar
|
|
22
|
Libby P, Ridker PM and Maseri A:
Inflammation and atherosclerosis. Circulation. 105:1135–1143. 2002.
View Article : Google Scholar
|
|
23
|
Brevetti G, Schiano V and Chiariello M:
Endothelial dysfunction: a key to the pathophysiology and natural
history of peripheral arterial disease? Atherosclerosis. 197:1–11.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ridker PM, Cushman M, Stampfer MJ, Tracy
RP and Hennekens CH: Plasma concentration of C-reactive protein and
risk of developing peripheral vascular disease. Circulation.
97:425–428. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Bloemenkamp DG, van den Bosch MA, Mali WP,
Tanis BC, Rosendaal FR, Kemmeren JM, Algra A, Visseren FL and van
der Graaf Y: Novel risk factors for peripheral arterial disease in
young women. Am J Med. 113:462–467. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Pradhan AD, Rifai N and Ridker PM: Soluble
intercellular adhesion molecule-1, soluble vascular adhesion
molecule-1, and the development of symptomatic peripheral arterial
disease in men. Circulation. 106:820–825. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Brevetti G, Oliva G, Silvestro A,
Scopacasa F and Chiariello M; Peripheral Arteriopathy and
Cardiovascular Events (PACE) Study Group. Prevalence, risk factors
and cardiovascular comorbidity of symptomatic peripheral arterial
disease in Italy. Atherosclerosis. 175:131–138. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wildman RP, Muntner P, Chen J,
Sutton-Tyrrell K and He J: Relation of inflammation to peripheral
arterial disease in the National Health and Nutrition Examination
Survey, 1999–2002. Am J Cardiol. 96:1579–1583. 2005.
|
|
29
|
Tzoulaki I, Murray GD, Lee AJ, Rumley A,
Lowe GD and Fowkes FG: C-reactive protein, interleukin-6, and
soluble adhesion molecules as predictors of progressive peripheral
atherosclerosis in the general population: Edinburgh Artery Study.
Circulation. 112:976–983. 2005. View Article : Google Scholar
|
|
30
|
Hoogeveen RC, Morrison A, Boerwinkle E,
Miles JS, Rhodes CE, Sharrett AR and Ballantyne CM: Plasma MCP-1
level and risk for peripheral arterial disease and incident
coronary heart disease: Atherosclerosis Risk in Communities study.
Atherosclerosis. 183:301–307. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Cassar K, Bachoo P, Ford I, Greaves M and
Brittenden J: Markers of coagulation activation, endothelial
stimulation and inflammation in patients with peripheral arterial
disease. Eur J Vasc Endovasc Surg. 29:171–176. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Tzoulaki I, Murray GD, Lee AJ, Rumley A,
Lowe GD and Fowkes FG: Inflammatory, haemostatic, and rheological
markers for incident peripheral arterial disease: Edinburgh Artery
Study. Eur Heart J. 28:354–362. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Fowkes FG, Housley E, Riemersma RA,
Macintyre CC, Cawood EH, Prescott RJ and Ruckley CV: Smoking,
lipids, glucose intolerance, and blood pressure as risk factors for
peripheral atherosclerosis compared with ischemic heart disease in
the Edinburgh Artery Study. Am J Epidemiol. 135:331–340. 1992.
|
|
34
|
Murabito JM, D’Agostino RB, Silbershatz H
and Wilson WF: Intermittent claudication: a risk profile from the
Framingham Heart Study. Circulation. 96:44–49. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Pryor WA and Stone K: Oxidants in
cigarette smoke: radicals, hydrogen peroxide, peroxynitrate, and
peroxynitrite. Ann NY Acad Sci. 686:12–27. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Morrow JD, Frei B, Longmire AW, Gaziano
JM, Lynch SM, Shyr Y, Strauss WE, Oates JA and Roberts LJ II:
Increase in circulating products of lipid perioxidation
(F2-isoprostanes) in smokers. Smoking as a cause of oxidative
damage. N Engl J Med. 332:1198–1203. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Baynes JW and Thorpe SR: Role of oxidative
stress in diabetic complications: a new perspective on an old
paradigm. Diabetes. 48:1–9. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Rahman I and Adcock IM: Oxidative stress
and redox regulation of lung inflammation in COPD. Eur Respir J.
28:219–242. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Hirsch AT, Criqui MH, Treat-Jacobson D,
Regensteiner JG, Creager MA, Olin JW, Krook SH, Hunninghake DB,
Comerota AJ, Walsh ME, McDermott MM and Hiatt WR: Peripheral
arterial disease detection, awareness, and treatment in primary
care. JAMA. 286:1317–1324. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Griendling KK, Ushio-Fukai M, Lassegue B
and Alexander RW: Angiotensin II signaling in vascular smooth
muscle. New concepts. Hypertension. 29:366–373. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Kranzhofer R, Schmidt J, Pfeiffer CA, Hagl
S, Libby P and Kubler W: Angiotensin induces inflammatory
activation of human vascular smooth muscle cells. Arterioscler
Thromb Vasc Biol. 19:1623–1629. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Hernandez-Presa M, Bustos C, Ortego M,
Tunon J, Renedo G, Ruiz-Ortega M and Egido J:
Angiotensin-converting enzyme inhibition prevents arterial nuclear
factor-kappa B activation, monocyte chemoattractant protein-1
expression, and macrophage infiltration in a rabbit model of early
accelerated atherosclerosis. Circulation. 95:1532–1541. 1997.
View Article : Google Scholar
|
|
43
|
Tummala PE, Chen XL, Sundell CL, Laursen
JB, Hammes CP, Alexander RW, Harrison DG and Medford RM:
Angiotensin II induces vascular cell adhesion molecule-1 expression
in rat vasculature: a potential link between the renin-angiotensin
system and atherosclerosis. Circulation. 100:1223–1229. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Cushing SD, Berliner JA, Valente AJ,
Territo MC, Navab M, Parhami F, Gerrity R, Schwartz CJ and Fogelman
AM: Minimally modified low density lipoprotein induces monocyte
chemotactic protein 1 in human endothelial cells and smooth muscle
cells. Proc Natl Acad Sci USA. 87:5134–5138. 1990. View Article : Google Scholar
|
|
45
|
Rajavashisth TB, Andalibi A, Territo MC,
Berliner JA, Navab M, Fogelman AM and Lusis AJ: Induction of
endothelial cell expression of granulocyte and macrophage
colony-stimulating factors by modified low-density lipoproteins.
Nature. 344:254–257. 1990. View
Article : Google Scholar : PubMed/NCBI
|
|
46
|
Li JJ and Fang CH: C-reactive protein is
not only an inflammatory marker but also a direct cause of
cardiovascular diseases. Med Hypotheses. 62:499–506. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Galkina E and Ley K: Vascular adhesion
molecules in atherosclerosis. Arterioscler Thromb Vasc Biol.
27:2292–2301. 2007. View Article : Google Scholar
|
|
48
|
Tedgui A and Mallat Z: Cytokines in
atherosclerosis: pathogenic and regulatory pathways. Physiol Rev.
86:515–581. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Braunersreuther V, Mach F and Steffens S:
The specific role of chemokines in atherosclerosis. Thromb Haemost.
97:714–721. 2007.PubMed/NCBI
|
|
50
|
Roldan V, Marin F, Lip GY and Blann AD:
Soluble E-selectin in cardiovascular disease and its risk factors.
A review of the literature. Thromb Haemost. 90:1007–1020.
2003.PubMed/NCBI
|
|
51
|
Nielsen LB: Atherogenecity of
lipoprotein(a) and oxidized low density lipoprotein: insight from
in vivo studies of arterial wall influx, degradation and efflux.
Atherosclerosis. 143:229–243. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Carmelli D, Fabsitz RR, Swan GE, Reed T,
Miller B and Wolf PA: Contribution of genetic and environmental
influences to ankle-brachial blood pressure index in the NHLBI Twin
Study. National Heart, Lung, and Blood Institute. Am J Epidemiol.
151:452–458. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Thomas JC, Vohra RS, Beer S, Bhatti K,
Ponnambalam S and Homer-Vanniasinkam S: Biomarkers in peripheral
arterial disease. Trends Cardiovasc Med. 19:147–151. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Fiessinger JN and Schäfer M: Trial of
iloprost versus aspirin treatmentfor critical limb ischaemia of
thromboangiitis obliterans. The TAO Study. Lancet. 335:555–557.
1990. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Dormandy J: Use of the prostacyclin
analogue iloprost in the treatment of patients with critical limb
ischaemia. Therapie. 46:319–322. 1991.PubMed/NCBI
|
|
56
|
Lessiani G, Vazzana N, Cuccurullo C, Di
Michele D, Laurora G, Sgrò G, Di Ruscio P, Simeone E, Di Iorio P,
Lattanzio S, Liani R, Ferrante E and Davì G: Inflammation,
oxidative stress and platelet activation in aspirin-treated
critical limb ischaemia: beneficial effects of iloprost. Thromb
Haemost. 105:321–328. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Miyashita Y, Saito S, Miyamoto A, Iida O
and Nanto S: Cilostazol increases skin perfusion pressure in
severely ischemic limbs. Angiology. 62:15–17. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Shalhoub J, Davies AH and Franklin IJ:
Cilostazol may improve outcome in critical limb ischemia. Int
Angiol. 28:363–366. 2009.PubMed/NCBI
|
|
59
|
Sigvant B, Wiberg-Hedman K, Bergqvist D,
Rolandsson O, Andersson B, Persson E and Wahlberg E: A
population-based study of peripheral arterial disease prevalence
with special focus on critical limb ischemia and sex differences. J
Vasc Surg. 45:1185–1191. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Folsom AR, Pankow JS, Tracy RP, Arnett DK,
Peacock JM, Hong Y, Djoussé L and Eckfeldt JH; Investigators of the
NHBLI Family Heart Study. Association of C-reactive protein with
markers of prevalent atherosclerotic disease. Am J Cardiol.
88:112–117. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Galis ZS and Khatri JJ: Matrix
metalloproteinases in vascular remodeling and atherogenesis: the
good, the bad, and the ugly. Circ Res. 90:251–262. 2002.PubMed/NCBI
|
|
62
|
Galis ZS, Johnson C, Godin D, Magid R,
Shipley JM, Senior RM and Ivan E: Targeted disruption of the matrix
metalloproteinase-9 gene impairs smooth muscle cell migration and
geometrical arterial remodeling. Circ Res. 91:852–859. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Galis ZS, Sukhova GK, Lark MW and Libby P:
Increased expression of matrix metalloproteinases and matrix
degrading activity in vulnerable regions of human atherosclerotic
plaques. J Clin Invest. 94:2493–2503. 1994. View Article : Google Scholar
|
|
64
|
Indelicato M, Navolanic PM, Pennisi G and
Mazzarino MC: Plasma levels and zymographic activities of matrix
metalloproteinases 2 and 9 in type II diabetics with peripheral
arterial disease. Vasc Med. 10:1–6. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Ley K: The role of selectins in
inflammation and disease. Trends Mol Med. 9:263–268. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Boulbou MS, Koukoulis GN, Vasiou KG,
Petinaki EA, Gourgoulianis KI and Fezoulidis IB: Increased soluble
E-selectin levels in type 2 diabetic patients with peripheral
arterial disease. Int Angiol. 23:18–24. 2004.PubMed/NCBI
|
|
67
|
Signorelli SS, Mazzarino MC, Di Pino L,
Malaponte G, Porto C, Pennisi G, Marchese G, Costa MP, Digrandi D,
Celotta G and Virgilio V: High circulating levels of cytokines
(IL-6 and TNFalpha), adhesion molecules (VCAM-1 and ICAM-1) and
selectins in patients with peripheral arterial disease at rest and
after a treadmill test. Vasc Med. 8:15–19. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Flex A, Gaetani E, Angelini F, Sabusco A,
Chillà C, Straface G, Biscetti F, Pola P, Castellot JJ Jr and Pola
R: Pro-inflammatory genetic profiles in subjects with peripheral
arterial occlusive disease and critical limb ischemia. J Intern
Med. 262:124–130. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Merten M and Thiagarajan P: P-selectin in
arterial thrombosis. Z Kardiol. 93:855–863. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Rao AK, Vaidyula VR, Bagga S, Jalagadugula
G, Gaughan J, White DB and Commerota AJ: Effect of
antiplateletagents clopidogrel, aspirin and cilastazol on
circulating tissue factor procoagulant activity in patients with
peripheral arterial disease. Thromb Haemost. 96:738–743.
2006.PubMed/NCBI
|
|
71
|
Dinarello CA: Blocking interleukin-1β in
acute and chronic autoinflammatory diseases. J Intern Med.
269:16–28. 2011.
|
|
72
|
Dinarello CA: IL-18: A TH1-inducing,
proinflammatory cytokine and new member of the IL-1 family. J
Allergy Clin Immunol. 103:11–24. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Saetre T, Enoksen E, Lyberg T, Stranden E,
Jørgensen JJ, Sundhagen JO and Hisdal J: Supervised exercise
training reduces plasma levels of the endothelial inflammatory
markers E-selectin and ICAM-I in patients with peripheral arterial
disease. Angiology. 62:301–305. 2011. View Article : Google Scholar
|
|
74
|
Libby P, Sukhova G, Lee RT and Galis ZS:
Cytokines regulate vascular functions related to stability of the
atherosclerotic plaque. J Cardiovasc Pharmacol. 25(Suppl 2):
S9–S12. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Fiotti N, Giansante C, Ponte E, Delbello
C, Calabrese S, Zacchi T, Dobrina A and Guarnieri G:
Atherosclerosis and inflammation. Patterns of cytokine regulation
in patients with peripheral arterial disease. Atherosclerosis.
145:51–60. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
McDermott MM, Guralnik JM, Corsi A, Albay
M, Macchi C, Bandinelli S and Ferrucci L: Patterns of inflammation
associated with peripheral arterial disease: the InCHIANTI study.
Am Heart J. 150:276–281. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Dinarello CA: Interleukin-1. Cytokine
Growth Factor Rev. 8:253–265. 1997. View Article : Google Scholar
|
|
78
|
Bresnihan B, Alvaro-Gracia JM, Cobby M,
Doherty M, Domljan Z, Emery P, Nuki G, Pavelka K, Rau R, Rozman B,
Watt I, Williams B, Aitchison R, McCabe D and Musikic P: Treatment
of rheumatoid arthritis with recombinant human interleukin-1
receptor antagonist. Arthritis Rheum. 41:2196–2204. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Malek TR and Castro I: Interleukin-2
receptor signaling: at the interface between tolerance and
immunity. Immunity. 33:153–165. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Lindholt JS and Shi GP: Chronic
inflammation, immune response, and infection in abdominal aortic
aneurysms. Eur J Vasc Endovasc Surg. 31:453–463. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Wan YY and Flavell RA: The roles for
cytokines in the generation and maintenance of regulatory T cells.
Immunol Rev. 212:114–130. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Khew-Goodall Y, Wadham C, Stein BN, Gamble
JR and Vadas MA: Stat6 activation is essential for interleukin-4
induction of P-selectin transcription in human umbilical vein
endothelial cells. Arterioscler Thromb Vasc Biol. 19:1421–1429.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Depalma RG, Hayes VW, Chow BK, Shamayevu
G, May PE and Zackarski LR: Ferritin levels, inflammatory
biomarkers, and mortality in peripheral arterial disease: a
substudy of the Iron (Fe) and Atherosclerosis Study (FeAST) Trial.
J Vasc Surg. 51:1498–1503. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Nylaende M, Kroese A, Stranden E, Morken
B, Sandbaek G, Lindahl AK, Arnesen H and Seljeflot I: Markers of
vascular inflammation are associated with the extent of
atherosclerosis assessed as angiographic score and treadmill
walking distances in patients with peripheral arterial occlusive
disease. Vasc Med. 11:21–28. 2006. View Article : Google Scholar
|
|
85
|
McDermott MM, Liu K, Ferrucci L, Tian L,
Guralnik JM, Tao H, Ridker PM and Criqui MH: Relation of
interleukin-6 and vascular cellular adhesion molecule-1 levels to
functional decline in patients with lower extremity peripheral
arterial disease. Am J Cardiol. 107:1392–1398. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Akira S, Taga T and Kishimoto T:
Interleukin-6 in biology and medicine. Adv Immunol. 54:1–78. 1993.
View Article : Google Scholar
|
|
87
|
Sabat R, Grütz G, Warszawska K, Kirsch S,
Witte E, Wolk K and Geginat J: Biology of interleukin-10. Cytokine
Growth Factor Rev. 21:331–344. 2010. View Article : Google Scholar
|
|
88
|
Libra M, Signorelli SS, Bevelacqua Y,
Navolanic PM, Bevelacqua V, Polesel J, Talamini R, Stivala F,
Mazzarino MC and Malaponte G: Analysis of G(-174)C IL-6
polymorphism and plasma concentrations of inflammatory markers in
patients with type 2 diabetes and peripheral arterial disease. J
Clin Pathol. 59:211–215. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Marino F, Guasti L, Tozzi M, Consuelo Maio
R, Castiglioni L, Rasini E, Schembri L, Maroni L, Legnaro M, De Leo
A, Piffaretti G, Castelli P, Venco A, Lecchini S and Cosentino M:
Angiotensin type 1 receptor expression and interleukin-8 production
in polymorphonuclear leukocytes of patients with peripheral
arterial disease. J Cardiovasc Pharmacol. 54:520–525. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Mallat Z, Besnard S, Duriez M, Deleuze V,
Emmanuel F, Bureau MF, Soubrier F, Esposito B, Duez H, Fievet C,
Staels B, Duverger N, Scherman D and Tedgui A: Protective role of
interleukin-10 in atherosclerosis. Circ Res. 85:e17–e24. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Mallat Z, Heymes C, Ohan J, Faggin E,
Leseche G and Tedgui A: Expression of interleukin-10 in advanced
human atherosclerotic plaques: relation to inducible nitric oxide
synthase expression and cell death. Arterioscler Thromb Vasc Biol.
19:611–616. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Tiret L, Godefroy T, Lubos E, Nicaud V,
Tregouet DA, Barbaux S, Schnabel R, Bickel C, Espinola-Klein C,
Poirier O, Perret C, Münzel T, Rupprecht HJ, Lackner K, Cambien F
and Blankenberg S; AtheroGene Investigators. Genetic analysis of
the interleukin-18 system highlights the role of the interleukin-18
gene in cardiovascular disease. Circulation. 112:643–650. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Anguera I, Miranda-Guardiola F, Bosch X,
Filella X, Sitges M, Marín JL, Betriu A and Sanz G: Elevation of
serum levels of the anti-inflammatory cytokine interleukin-10 and
decreased risk of coronary events in patients with unstable angina.
Am Heart J. 144:811–817. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Smith DA, Irving SD, Sheldon J, Cole D and
Kaski JC: Serum levels of the antiinflammatory cytokine
interleukin-10 are decreased in patients with unstable angina.
Circulation. 104:746–749. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Blanco E, Moñux G, Mas A, Serrano FJ, de
la Concha EG and Urcelay E: Role of IL-10 promoter polymorphisms in
the development of severe aorto-iliac occlusive disease. Hum
Immunol. 69:651–654. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Heeschen C, Dimmeler S, Hamm CW,
Fichtlscherer S, Boersma E, Simoons ML and Zeiher AM; CAPTURE Study
Investigators. Serum level of the antiinflammatory cytokine
interleukin-10 is an important prognostic determinant in patients
with acute coronary syndromes. Circulation. 107:2109–2114. 2003.
View Article : Google Scholar
|
